$222.26
Insights on Madrigal Pharmaceuticals, Inc.
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 67.8%
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 162.1%
0.68%
Downside
Day's Volatility :2.89%
Upside
2.22%
46.12%
Downside
52 Weeks Volatility :62.88%
Upside
31.12%
Period | Madrigal Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 1.89% | -0.7% | 0.0% |
6 Months | 67.77% | 6.6% | 0.0% |
1 Year | -21.08% | 3.7% | -1.5% |
3 Years | 88.41% | 14.0% | -21.8% |
Market Capitalization | 4.9B |
Book Value | $20.39 |
Earnings Per Share (EPS) | -19.99 |
PEG Ratio | 0.0 |
Wall Street Target Price | 394.54 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -47.41% |
Return On Equity TTM | -123.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -380.0M |
Diluted Eps TTM | -19.99 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -23.48 |
EPS Estimate Next Year | -14.46 |
EPS Estimate Current Quarter | -5.28 |
EPS Estimate Next Quarter | -5.05 |
What analysts predicted
Upside of 77.51%
Sell
Neutral
Buy
Madrigal Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. | -19.38% | 67.77% | -21.08% | 88.41% | 116.31% |
Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. | NA | NA | 0.0 | -23.48 | -1.24 | -0.47 | NA | 20.39 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. | Buy | $4.9B | 116.31% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
HHG PLC
Baker Bros Advisors LP
venBio Select Advisor LLC
Vanguard Group Inc
BlackRock Inc
RTW INVESTMENTS, LLC
Madrigal Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read Moremadrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Organization | Madrigal Pharmaceuticals, Inc. |
Employees | 376 |
CEO | Dr. Rebecca A. Taub M.D. |
Industry | Health Technology |
Endeavor Group Holdings, Inc.
$222.26
-2.66%
Associated Banc-corp
$222.26
-2.66%
Assetmark Financial Holdings Inc
$222.26
-2.66%
Essential Utilities Inc.
$222.26
-2.66%
Vanguard Ultra Short Bond Et
$222.26
-2.66%
Surgery Partners Inc
$222.26
-2.66%
Sl Green Realty Corp.
$222.26
-2.66%
Janus Henderson Mortgage-backed Securities Etf
$222.26
-2.66%
Goldman Sachs Activebeta Int
$222.26
-2.66%